Liposcience, Inc.

Thomas M O'Connell

James D Otvos

Dennis W Bennett

Justyna E Wolak-Dinsmore

Irina Y Shalaurova

Elias J Jeyarajah

Kelly Mercier

Stanley Leon Hazen

Steven P Matyus

Stanley L Hazan

Kelly A Mercier

A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide ('TMAO'). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 &#x3bc;M or urine with a normal biologic range of between about 0-1000 &#x3bc;M.

NMR quantification of TMAO

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.

Multi-parameter diabetes risk evaluations

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.

Growing community of inventors

Chapel Hill, NC, United States of America

Thomas M O'Connell